JAMA Oncology

@JAMAOnc · Chicago, IL · joined 15 Sep 2014

JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

50 783Followers

506Following

18 808Posts total

10.4KViews on collected posts

Últimas publicaciones

JAMA Oncology@JAMAOnc19 Sep

@JAMAOnc 1% by 2026!. 4 views · 0 likes · 0 reposts · 0 replies Open on X →

JAMA Oncology@JAMAOnc18 Sep

@JAMAOnc https://t.co/WyBtYmPu1j

GIF

93 views · 2 likes · 0 reposts · 0 replies Open on X →

JAMA Oncology@JAMAOnc18 Sep

Prebiopsy #MRI use before #ProstateCancer biopsy increased in the US from 2017 to 2026, reaching 64.1% of biopsy-naive patients, but uptake remained incomplete. https://t.co/FEoD6qtwCW https://t.co/YvLQteqZrC

2K views · 20 likes · 5 reposts · 4 replies Open on X →

JAMA Oncology@JAMAOnc18 Sep

💬Editorial: In HPV 16–positive recurrent or metastatic #HeadAndNeckCancer, PDS0101 plus pembrolizumab demonstrated activity in immune checkpoint inhibitor–naive disease but not after prior immune checkpoint inhibitor exposure. https://t.co/fwYwO4jAPy https://t.co/tlzO6UlqFe

1.9K views · 5 likes · 4 reposts · 0 replies Open on X →

JAMA Oncology@JAMAOnc17 Sep

Meta-analysis: Among #HeadAndNeckCancer patients with PD-L1 CPS <1, #ImmuneCheckpointInhibitors were linked to poorer survival outcomes, including significantly reduced overall survival in recurrent/metastatic disease. https://t.co/6XQjl1DujV https://t.co/0FLl1PIve7

2.9K views · 22 likes · 7 reposts · 0 replies Open on X →

JAMA Oncology@JAMAOnc17 Sep

In #HPV16-positive recurrent or metastatic #HeadAndNeckCancer, PDS0101 plus #Pembrolizumab showed antitumor activity and manageable safety in immune checkpoint inhibitor–naive patients, but no objective responses in resistant patients. https://t.co/MmBkFHDrK4 https://t.co/KNID0Co

1.8K views · 15 likes · 2 reposts · 1 replies Open on X →

JAMA Oncology@JAMAOnc10 Sep

In persistent, recurrent, or metastatic #CervicalCancer, first-line #Pembrolizumab plus chemotherapy with or without bevacizumab maintained overall survival and progression-free survival benefit at 5 years, with no new safety signals observed. https://t.co/kHFZZRmovN 1.9K views · 7 likes · 3 reposts · 2 replies Open on X →

Frente a cuentas del mismo tamaño

7 publicaciones de los últimos 90 días, junto al rango de 10K–100K seguidores. alcance normal para su tamaño, reacción más débil que la mayoría.

Visualizaciones medianas1 854esta cuenta953mediana de 10K–100K

Alcance, %3.65%esta cuenta3.62%mediana de 10K–100K

Interacción, %1.01%esta cuenta1.51%mediana de 10K–100K

Métrica	Esta cuenta	Mediana de 10K–100K	Proporción
Visualizaciones medianas por publicación	1 854	953	1.95×
Alcance (visualizaciones ÷ seguidores)	3.65%	3.62%	1.01×
Tasa de interacción	1.01%	1.51%	0.67×

Otras cuentas de este rango → Comparar con otra cuenta → Cómo se construyen estas referencias →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

1.9K10 Sep

1.8K17 Sep

2.9K

1.9K18 Sep

419 Sep

Last 7 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.64%10 Sep

1.01%17 Sep

1.01%

0.49%18 Sep

1.48%

2.15%

0.00%19 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.51%.

What the audience does

Likes62.8%71 in total

Reposts18.6%21 in total

Replies6.2%7 in total

Bookmarks12.4%14 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Últimas publicaciones

Frente a cuentas del mismo tamaño

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Cuentas similares